Načítá se...
The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice
Peroxisome Proliferator Activated Receptor (PPAR)-α is a key regulator of lipid metabolism and recent studies reveal it also regulates inflammation in several different disease models. Gemfibrozil, an agonist of PPAR-α, is a FDA approved drug for hyperlipidemia and has been shown to inhibit clinical...
Uloženo v:
| Vydáno v: | Exp Neurol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5518476/ https://ncbi.nlm.nih.gov/pubmed/21963672 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.expneurol.2011.09.023 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|